Clinical Report: Reversible Myelodysplastic Syndrome Induced by Sodium Valproate

Overview

This report details a rare case of sodium valproate-induced reversible myelodysplastic syndrome (MDS) in a pediatric patient. The child's hematological parameters normalized after a dose adjustment of VPA, highlighting the importance of monitoring for hematological toxicity in children receiving this medication.

Background

Sodium valproate (VPA) is a widely used antiepileptic drug, effective for treating various forms of epilepsy in children. However, it carries risks of hematological toxicity, including myelodysplastic syndrome (MDS), which is particularly concerning in pediatric populations. Understanding the reversibility of such complications is crucial for optimizing treatment and ensuring patient safety.

Data Highlights

Key Findings

• A 9-year-old boy developed pancytopenia and MDS after 6 months of VPA therapy.
• Hematological parameters normalized within 3 months following a reduction in VPA dosage.
• Bone marrow examination post-dose adjustment showed resolution of dysplastic features.
• Seizure control was maintained without relapse during the dose adjustment period.
• This case emphasizes the dose-dependent nature of VPA-induced MDS.

Clinical Implications

Healthcare providers should conduct regular hematological monitoring in pediatric patients receiving sodium valproate to detect potential toxicities early. Dose adjustments may lead to the resolution of hematological abnormalities, allowing for continued seizure management without compromising patient safety.

Conclusion

This case underscores the importance of vigilance in monitoring for hematological side effects in children treated with sodium valproate, as timely interventions can lead to the reversal of serious complications.

Related Resources & Content

1. Frontiers | Case Report: Reversible Myelodysplastic Syndrome Secondary to Sodium Valproate in an Epileptic Child
2. American Epilepsy Society Clinical Practice Guideline: Infantile Epilepsy - PMC
3. BMC Psychiatry (Springer) — An Uncommon Instance of Isovaleric Acidemia Accompanied by Schizophrenia: A Case Study
4. Frontiers in Pediatrics — Overreliance on EEG Normalization: A Case Report of DEE-SWAS Treated as Presumed NCSE Leading to Avoidable Escalation
5. Frontiers in Oncology — Parvovirus B19 infection preceding the diagnosis of childhood myelodysplastic syndrome with low blasts: a case report
6. Open Forum Infectious Diseases — Diagnosis of Subacute Sclerosing Panencephalitis Induced by Measles Virus Through Clinical and Molecular Approaches
7. American Epilepsy Society Clinical Practice Guideline: Infantile Epilepsy - PMC
8. label
9. Frontiers | Case Report: Reversible Myelodysplastic Syndrome Secondary to Sodium Valproate in an Epileptic Child